PDF(Pubmed)
Abstract：
Radionuclide probes-targeted prostate-specific membrane antigen (PSMA) is used in diagnosis and treatment of prostate cancer (PCa). Recent studies have shown that PSMA is expressed in the tumor neovascular endothelium, such as in malignant liver tumors. We report a case of PCa with incidental intrahepatic cholangiocarcinoma (ICC) detection using 18F-PSMA-1007 and 18F-fluorodeoxyglucose (FDG) positron emission topography (PET)/MRI.18F-PSMA-1007 PET/MRI of our patient with PCa showed that one liver lesion had high PSMA uptake. 18F-FDG PET/MRI revealed minimal FDG uptake in the liver lesion. Histopathological examination revealed that the liver lesion was moderately to poorly differentiated cholangiocarcinoma. Our studies, along with others, demonstrated that malignant liver tumors, such as ICC, hepatocellular carcinoma (HCC), and combined hepatocellular-cholangiocarcinoma (CHC), and benign lesions, such as benign liver hemangioma, focal nodular hyperplasia, focal inflammation and steatosis, vascular malformation, and fatty sparing, exhibited elevated PSMA uptake. Moreover, PSMA-PET was superior to FDG-PET in detecting ICC and HCC, indicating that PSMA-PET may be used as alternative staging and to identify patients for PSMA-targeted therapy.
摘要：
放射性核素探针靶向前列腺特异性膜抗原（PSMA）用于前列腺癌（PCa）的诊断和治疗。最近的研究表明，PSMA在肿瘤新生血管内皮细胞中表达，例如在肝脏恶性肿瘤中。我们报告了一例使用18F-PSMA-1007和18F-氟脱氧葡萄糖（FDG）正电子发射形貌（PET）/MRI.18F-PSMA-1007PET/MRI检测的偶发性肝内胆管癌（ICC）的PCa病例，我们的PCa患者有一个肝脏病变有较高的PSMA摄取。18F-FDGPET/MRI显示肝脏病变中FDG摄取最少。组织病理学检查显示肝脏病变为中度至低分化胆管癌。我们的研究,和其他人一起,证明了肝脏恶性肿瘤，比如ICC，肝细胞癌（HCC），合并肝细胞胆管癌（CHC），良性病变,如良性肝血管瘤，局灶性结节增生,局灶性炎症和脂肪变性,血管畸形,和脂肪的节省，显示PSMA摄取升高。此外，PSMA-PET在检测ICC和HCC方面优于FDG-PET，这表明PSMA-PET可用作替代分期，并可用于确定PSMA靶向治疗的患者。
